The therapeutic potential of CRTH2/DP2 beyond allergy and asthma

The document from 2017 reviews the role of the CRTH2/DP2 receptor, which is activated by prostaglandin D2 (PGD2), in various diseases beyond allergy and asthma, including the nervous system, kidney, intestine, lung, hair and skin, bone and cartilage, and cancer. It suggests that CRTH2 antagonists could be a potential therapeutic target for a wide range of conditions due to their involvement in immune and inflammatory responses. The review discusses the effects of CRTH2 antagonists in clinical trials for asthma, allergic rhinitis, and eosinophilic esophagitis, and their potential in treating inflammatory bowel diseases, cognitive dysfunction, autoimmune diseases, lung and kidney fibrosis, and androgenic alopecia. The document indicates that while the role of CRTH2 in cancer is still unclear, its broad presence in various cell types and tissues makes it a promising target for future therapeutic interventions.